EUVIMEDEUVIMED entdecken
Fallbericht

Identification of a Novel RUNX1::STX2 Fusion in Mixed‐Phenotype Acute Leukemia (MPAL) With BCR::ABL1

Yuan Long, Qi Xu iD, Jing Li, Bei-Cai Liu, Peng Cheng, Jun Luo, Shengbin Zhao, Ping Chen, Zhen-Fang Liu

Molecular Carcinogenesis · 2025

DOI: 10.1002/mc.23850 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Yuan Long und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Oncogene Proteins, Fusion, Fusion Proteins, bcr-abl. Die Arbeit nennt 15 Literaturangaben. Gefördert von: This work was supported by National Natural Science Foundation of China (Grant No. 82160039)., National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mixed phenotype acute leukemia (MPAL) is a rare type of acute leukemia (AL), MPAL with BCR::ABL1 fusion is the main subtype of MPAL, mainly affecting adult males. It is an acute leukemia with unique clinical and biological characteristics that involve both the myeloid and lymphatic systems. Gene fusion plays a crucial role in the pathogenesis, diagnosis, prognosis assessment, and treatment of leukemia. We present the first discovery of a novel fusion of RUNX1::STX2 in this subtype, which is co‐expressed with BCR::ABL1 fusion. RUNX1 is a crucial transcription factor for hematopoietic differentiation, frequently found to be abnormal in AML, while STX2 may play a role in cancer progression. The RUNX1::STX2 fusion protein may act as the primary negative regulator of wild‐type RUNX1, influencing normal cell differentiation and proliferation, consequently elevating the risk of leukemia. The gene fusion status of this patient is unique and complex, requiring further exploration to understand its functional significance in leukemia progression and treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitOncogene Proteins, FusionFusion Proteins, bcr-ablHumansMaleLeukemia, Biphenotypic, AcutePhenotypeAdult

Stichwörter der Autor:innen

BCR::ABL1RUNX1RUNX1::STX2STX2co‐expressionmixed‐phenotype acute leukemia

Substanzen

Core Binding Factor Alpha 2 SubunitRUNX1 protein, humanOncogene Proteins, FusionFusion Proteins, bcr-ablBCR-ABL1 fusion protein, human

Autor:innen und Institutionen

  • Department of Hematopathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China.
  • Suzhou Jsuniwell Medical Laboratory, Suzhou, China.

ORCID-Profile: Qi Xu

Förderung

  • This work was supported by National Natural Science Foundation of China (Grant No. 82160039).
  • National Natural Science Foundation of China

Zitieren

APA

Long, Y., Xu, Q., Li, J., Liu, B. C., Cheng, P., Luo, J., Zhao, S., Chen, P., & Liu, Z. F. (2025). Identification of a Novel RUNX1::STX2 Fusion in Mixed‐Phenotype Acute Leukemia (MPAL) With BCR::ABL1. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23850

Vancouver

Long Y, Xu Q, Li J, Liu BC, Cheng P, Luo J, et al. Identification of a Novel RUNX1::STX2 Fusion in Mixed‐Phenotype Acute Leukemia (MPAL) With BCR::ABL1. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23850

BibTeX
@article{Long2025,
  author = {Long, Yuan and Xu, Qi and Li, Jing and Liu, Bei-Cai and Cheng, Peng and Luo, Jun and Zhao, Shengbin and Chen, Ping and Liu, Zhen-Fang},
  title = {Identification of a Novel RUNX1::STX2 Fusion in Mixed‐Phenotype Acute Leukemia (MPAL) With BCR::ABL1},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  doi = {10.1002/mc.23850}
}
Kostenlos starten →